Australian Public Assessment Report for ivermectin – Stromectol Tablets, Product Information (PM-2012-01113-3-2) (2013)

Government Record · Therapeutic Goods Administration (Australia); sponsor Merck Sharp & Dohme (Australia) Pty Ltd · October 30, 2013

Therapeutic Goods Administration (Australia), 2013-10-30: Australia's approved product information for Stromectol, listing onchocerciasis, strongyloidiasis and two scabies indications.

STROMECTOL (ivermectin) is indicated for the treatment of:

7 (PDF page 7)

Therapeutic Goods Administration (Australia), 2013-10-30: Australia's approved product information for Stromectol, listing onchocerciasis, strongyloidiasis and two scabies indications. C6 Australia. The live TGA host refused a command-line fetch (301 with no body); the document was read from the Internet Archive capture of 2025-03-14, cited in archive_url, and the live URL is given as source_url. Indications as printed: 'a) onchocerciasis and intestinal strongyloidiasis (anguillulosis). b) crusted scabies in conjunction with topical therapy. c) human sarcoptic scabies when prior topical treatment has failed or is contraindicated.' The AusPAR records the sponsor as Merck Sharp & Dohme (Australia) Pty Ltd and the application as PM-2012-01113-3-2. Study type: regulatory record.